Register for free
Recent Quotes
My Watchlist
Indicators
Business Insurance Index
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Y-mAbs Therapeutics, Inc. - Common Stock (NQ:YMAB)

4.230 +0.060 (+1.44%)
Streaming Delayed Price Updated: 4:00 PM EDT, May 20, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 112,150
Open 4.140
Bid (Size) 3.650 (3)
Ask (Size) 5.060 (1)
Prev. Close 4.170
Today's Range 4.130 - 4.310
52wk Range 3.550 - 16.11
Shares Outstanding 44,789,076
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
What 7 Analyst Ratings Have To Say About Y-mAbs Therapeutics
Via Benzinga
Preview: Y-mAbs Therapeutics's Earnings
Via Benzinga

Performance

YTD
-46.9%
-46.9%
1 Month
-12.2%
-12.2%
3 Month
-31.8%
-31.8%
6 Month
-60.5%
-60.5%
1 Year
-64.2%
-64.2%

More News

Read More
12 Health Care Stocks Moving In Monday's After-Market Session
Via Benzinga
12 Health Care Stocks Moving In Tuesday's Intraday Session
Via Benzinga
Breaking Down Y-mAbs Therapeutics: 5 Analysts Share Their Views
Via Benzinga
Forecasting The Future: 4 Analyst Projections For Y-mAbs Therapeutics
Via Benzinga
Decoding 5 Analyst Evaluations For Y-mAbs Therapeutics
Via Benzinga
Beyond The Numbers: 4 Analysts Discuss Y-mAbs Therapeutics Stock
Via Benzinga
Earnings Scheduled For May 13, 2025
Via Benzinga
Top movers in Thursday's pre-market session
Via Chartmill
12 Health Care Stocks Moving In Thursday's Pre-Market Session
Via Benzinga
Acelyrin, Tesla And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session
Via Benzinga
Y-mAbs' Omburtamab Failure: The Critical Turning Point And $19.65M Shareholder Settlement
Via Benzinga
Examining the Future: Y-mAbs Therapeutics's Earnings Outlook
Via Benzinga
Navigating 8 Analyst Ratings For Y-mAbs Therapeutics
Via Benzinga
Assessing Y-mAbs Therapeutics: Insights From 5 Financial Analysts
Via Benzinga
Cracking The Code: Understanding Analyst Reviews For Y-mAbs Therapeutics
Via Benzinga
Earnings Scheduled For March 4, 2025
Via Benzinga
Positive Outlook For Novartis As Company Capitalizes On Growing Treatment Opportunities, Analyst Highlights
Via Benzinga
Why Y-mAbs Therapeutics Stock Got Mashed on Monday
Via The Motley Fool
YMAB Stock Earnings: Y-mAbs Therapeutics Misses EPS, Misses Revenue for Q2 2024
Via InvestorPlace
Why Ainos Shares Are Trading Higher By Around 38%; Here Are 20 Stocks Moving Premarket
Via Benzinga
Pomerantz LLP Announces Proposed Class Action Settlement on Behalf of Purchasers of Stock of Y-mAbs Therapeutics, Inc. - YMAB
From Pomerantz LLP
Via GlobeNewswire
MSC Industrial Direct, Radius Recycling And 3 Stocks To Watch Heading Into Tuesday
Via Benzinga
YMAB Stock Earnings: Y-mAbs Therapeutics Misses EPS, Misses Revenue for Q1 2024
Via InvestorPlace

Frequently Asked Questions

Is Y-mAbs Therapeutics, Inc. - Common Stock publicly traded?
Yes, Y-mAbs Therapeutics, Inc. - Common Stock is publicly traded.
What exchange does Y-mAbs Therapeutics, Inc. - Common Stock trade on?
Y-mAbs Therapeutics, Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Y-mAbs Therapeutics, Inc. - Common Stock?
The ticker symbol for Y-mAbs Therapeutics, Inc. - Common Stock is YMAB on the Nasdaq Stock Market
What is the current price of Y-mAbs Therapeutics, Inc. - Common Stock?
The current price of Y-mAbs Therapeutics, Inc. - Common Stock is 4.230
When was Y-mAbs Therapeutics, Inc. - Common Stock last traded?
The last trade of Y-mAbs Therapeutics, Inc. - Common Stock was at 05/20/25 04:00 PM ET
What is the market capitalization of Y-mAbs Therapeutics, Inc. - Common Stock?
The market capitalization of Y-mAbs Therapeutics, Inc. - Common Stock is 189.46M
How many shares of Y-mAbs Therapeutics, Inc. - Common Stock are outstanding?
Y-mAbs Therapeutics, Inc. - Common Stock has 189M shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.

Business Insurance is a singular, authoritative news and information source for executives focused upon risk management, risk transfer and risk financing.

Never miss important news. Subscribe to our newsletter.
Register for free

Information

Copyright 2024. BUSINESS INSURANCE HOLDINGS